DF
VRTX icon

Donoghue Forlines’s Vertex Pharmaceuticals VRTX Stock Holding History

Donoghue Forlines’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-3,323
Closed -$1.56M – 275
2024
Q2 		$1.56M Sell
3,323
-434
-12% -$188K 0.44% 49
2024
Q1 		$1.57M Buy
3,757
+2,357
+168% +$996K 0.45% 68
2023
Q4 		$570K Sell
1,400
-3,896
-74% -$1.44M 0.18% 151
2023
Q3 		$1.84M Sell
5,296
-169
-3% -$59.1K 0.66% 25
2023
Q2 		$1.92M Sell
5,465
-94
-2% -$31.7K 0.6% 25
2023
Q1 		$1.75M Buy
5,559
+74
+1% +$22.2K 0.63% 24
2022
Q4 		$1.58M Buy
5,485
+1,517
+38% +$462K 0.56% 36
2022
Q3 		$1.15M Buy
3,968
+213
+6% +$61.3K 0.41% 24
2022
Q2 		$1.06M Buy
3,755
+527
+16% +$141K 0.28% 83
2022
Q1 		$842K Buy
+3,228
New +$766K 0.18% 179
2021
Q3 		– Sell
-5,151
Closed -$1.04M – 245
2021
Q2 		$1.04M Buy
5,151
+345
+7% +$72.2K 0.19% 133
2021
Q1 		$1.03M Buy
4,806
+11
+0.2% +$2.42K 0.2% 129
2020
Q4 		$1.13M Buy
+4,795
New +$1.1M 0.22% 117

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Donoghue Forlines's VRTX Position: Q3 2024 in Review

Donoghue Forlines sold out of Vertex Pharmaceuticals (VRTX) in Q3 2024, closing a stake of 3,323 shares — an estimated $1.56M sold.

Donoghue Forlines first reported a position in VRTX in Q4 2020 and held it in 13 quarters. The position peaked at $1.92M in Q2 2023. 1,544 funds tracked by Wall St. Rank hold VRTX as of Q3 2024.

  • Donoghue Forlines reported no remaining Vertex Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Donoghue Forlines sold 3,323 Vertex Pharmaceuticals shares in Q3 2024, an estimated $1.56M.
  • Donoghue Forlines first reported a position in Vertex Pharmaceuticals in Q4 2020 and held it in 13 quarters.
  • Donoghue Forlines's Vertex Pharmaceuticals position peaked at $1.92M in Q2 2023.
  • 1,544 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2024.

Based on Donoghue Forlines's 13F filing for Q3 2024, filed 13 Nov 2024.